全文获取类型
收费全文 | 3935篇 |
免费 | 606篇 |
国内免费 | 64篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 71篇 |
妇产科学 | 68篇 |
基础医学 | 469篇 |
口腔科学 | 148篇 |
临床医学 | 384篇 |
内科学 | 801篇 |
皮肤病学 | 43篇 |
神经病学 | 383篇 |
特种医学 | 71篇 |
外国民族医学 | 2篇 |
外科学 | 427篇 |
综合类 | 151篇 |
预防医学 | 254篇 |
眼科学 | 30篇 |
药学 | 460篇 |
中国医学 | 69篇 |
肿瘤学 | 758篇 |
出版年
2024年 | 2篇 |
2023年 | 199篇 |
2022年 | 160篇 |
2021年 | 321篇 |
2020年 | 402篇 |
2019年 | 353篇 |
2018年 | 304篇 |
2017年 | 333篇 |
2016年 | 253篇 |
2015年 | 294篇 |
2014年 | 370篇 |
2013年 | 450篇 |
2012年 | 221篇 |
2011年 | 200篇 |
2010年 | 164篇 |
2009年 | 126篇 |
2008年 | 129篇 |
2007年 | 89篇 |
2006年 | 55篇 |
2005年 | 27篇 |
2004年 | 42篇 |
2003年 | 34篇 |
2002年 | 23篇 |
2001年 | 13篇 |
2000年 | 8篇 |
1999年 | 5篇 |
1998年 | 4篇 |
1997年 | 7篇 |
1996年 | 4篇 |
1995年 | 1篇 |
1994年 | 5篇 |
1993年 | 3篇 |
1992年 | 2篇 |
1991年 | 1篇 |
1987年 | 1篇 |
排序方式: 共有4605条查询结果,搜索用时 31 毫秒
1.
2.
3.
4.
动脉粥样硬化是引起大多数心血管疾病的主要原因,但其发病机制复杂,目前尚未完全阐明。越来越多的研究表明,脂质代谢紊乱可能在动脉粥样硬化的形成和发展中发挥重要作用。神经鞘脂作为一类参与机体结构组成、具有信号转导功能的生物活性脂质,在心血管疾病患者的血液和病变血管中水平异常,某些神经鞘脂分子可能是心血管疾病潜在的生物标志物和治疗靶点。文章综述神经鞘脂对动脉粥样硬化的影响和调控机制,为防治动脉粥样硬化寻找新的思路和分子靶点。 相似文献
5.
生物信息学是一门对基因组学和蛋白质组学进行研究的新兴学科,是生物学、计算机科学、信息工程和统计学的综合交叉学科。在眼科生物基因研究中,角膜、晶状体、房水、玻璃体和视网膜因富含大量的生物信息,是理想的生物信息学研究对象。基因组学检测技术的高效性和准确性有助于对眼科肿瘤及遗传疾病相关差异表达基因的筛查。蛋白质组学有助于分析眼科疾病状态下眼内液体或细胞中基因表达高低所引起的蛋白表达谱及功能改变,从而揭示疾病的发生机制。本文主要综述生物信息学在眼科疾病的应用,并初步展望其对相关疾病治疗的影响、目前存在的问题及未来的发展趋势。 相似文献
6.
《Journal of Cardiovascular Computed Tomography》2022,16(1):54-122
AimThis clinical practice guideline for the evaluation and diagnosis of chest pain provides recommendations and algorithms for clinicians to assess and diagnose chest pain in adult patients.MethodsA comprehensive literature search was conducted from November 11, 2017, to May 1, 2020, encompassing randomized and nonrandomized trials, observational studies, registries, reviews, and other evidence conducted on human subjects that were published in English from PubMed, EMBASE, the Cochrane Collaboration, Agency for Healthcare Research and Quality reports, and other relevant databases. Additional relevant studies, published through April 2021, were also considered.StructureChest pain is a frequent cause for emergency department visits in the United States. The “2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain” provides recommendations based on contemporary evidence on the assessment and evaluation of chest pain. This guideline presents an evidence-based approach to risk stratification and the diagnostic workup for the evaluation of chest pain. Cost-value considerations in diagnostic testing have been incorporated, and shared decision-making with patients is recommended. 相似文献
7.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
8.
9.
Troels D. Christensen Christina Jensen Ole Larsen Bonna Leerhøy Carsten P. Hansen Kasper Madsen Dan Høgdall Morten A. Karsdal Inna M. Chen Dorte Nielsen Julia S. Johansen Nicholas Willumsen 《International journal of cancer. Journal international du cancer》2023,152(5):1036-1049
Biliary tract cancer (BTC) is characterized by a desmoplastic extracellular matrix (ECM). We tested the diagnostic and prognostic use of seven circulating biomarkers of ECM remodeling: pro-peptides of type III collagen (PRO-C3), VI (PRO-C6) and XI (PRO-C11), matrix metalloprotease (MMP) degraded type III collagen (C3M) and type IV collagen (C4M) fragments, granzyme B degraded type IV collagen fragments (C4G) and MMP degraded and citrullinated vimentin (VICM) a marker of macrophage activation. The study included 269 patients with all stages of BTC and 49 patients with benign biliary tract diseases. Serum samples from BTC patients were collected before surgery, or before first- or second-line chemotherapy. C3M, C4M, PRO-C3, PRO-C6, PRO-C11 and VICM levels were elevated in patients with BTC compared to patients with benign disease. Receiver operating characteristics curve analyses identified PRO-C3 (area under curve [AUC] = 0.87) as the ECM marker with the best diagnostic performance. The ECM biomarkers correlated with inflammation biomarkers (C-reactive protein [CRP], interleukin-6 [IL-6] and YKL-40) but not with CA19-9. To investigate prognostic performance, patients were split into three cohorts (first-line, second-line and surgery). Elevated ECM biomarker levels were associated with short overall survival (OS), but only pretreatment PRO-C3 and PRO-C6 were associated with OS in both the first-line and second-line settings when adjusting for CA19-9, performance status and stage in a multivariate Cox-regression analyses. Our results indicate that collagen remodeling is increased in patients with BTC and associated with survival. The collagen pro-peptides (PRO-C3 and PRO-C6) could be used as novel biomarkers in these patients. 相似文献
10.